SCHEMBL4044007

SCHEMBL4044007

Nc1nc(Nc2ccc3c(c2)OCO3)nn1-c1ccccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 16/20 0.62
KIT P10721 11/20 0.62
IRAK4 Q9NWZ3 4/20 0.62
AURKA O14965 2/20 0.62
JAK2 O60674 2/20 0.62
AXL P30530 4/20 0.56
ABL1 P00519 1/20 0.52
LCK P06239 1/20 0.52
LYN P07948 1/20 0.52
MET P08581 1/20 0.52
PDGFRB P09619 1/20 0.52
SRC P12931 1/20 0.52
FGFR3 P22607 1/20 0.52
KDR P35968 1/20 0.52
JAK3 P52333 1/20 0.52
TEK Q02763 1/20 0.52
KARS1 Q15046 1/20 0.52
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043587 0.93 FLT3 (0.64) FLT3KITIRAK4AURKAJAK2
SCHEMBL2089408 0.86 IDO1 (0.50) FLT3KITIRAK4AURKAJAK2
SCHEMBL4042908 0.83 MAPT (0.47) FLT3KITIRAK4AURKAJAK2
SCHEMBL4042334 0.83 ULK1 (0.47) FLT3KITIRAK4AURKAJAK2
SCHEMBL4219839 0.82 AXL (0.70) FLT3KITIRAK4AURKAJAK2
SCHEMBL12780376 0.81 FLT3 (0.43) FLT3KITIRAK4AURKAJAK2
SCHEMBL12845571 0.81 LMNA (0.45) FLT3KITIRAK4AURKAJAK2
SCHEMBL6224723 0.81 ULK1 (0.44) FLT3KITIRAK4AURKAJAK2
SCHEMBL4042371 0.80 ULK1 (0.54) FLT3KITIRAK4AURKAJAK2
SCHEMBL4046024 0.80 FLT3 (0.56) FLT3KITIRAK4AURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885KIT 1144/4885IRAK4 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.